Coya Therapeutics stock gains on new data from Alzheimer's study
Shares of Coya Therapeutics Inc. (COYA) gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a study of its investigational therapy COYA 301 in patients with mild to moderate Alzheimer's disease. An open-label study in eight patients found a decrease in neuroinflammation following treatment with the therapy, the company said in a release. Coya previously reported that patients in the COYA 301 trial achieved a significant improvement in cognitive function.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 07, 2023 08:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
, 
, 
Copyright ©2023. All rights reserved.